Valomaciclovir
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Valomaciclovir
- Accession Number
- DB06575
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Valomaciclovir (DB06575)
- Weight
- Average: 352.395
Monoisotopic: 352.185903277 - Chemical Formula
- C15H24N6O4
- Synonyms
- Valomaciclovir
- External IDs
- EPB-348
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Investigated for use/treatment in herpes zoster infections and viral infection.
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbiraterone The serum concentration of Valomaciclovir can be increased when it is combined with Abiraterone. Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Valomaciclovir. Acetazolamide Acetazolamide may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy. Adalimumab The serum concentration of Valomaciclovir can be decreased when it is combined with Adalimumab. Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Valomaciclovir. Allopurinol The serum concentration of Valomaciclovir can be increased when it is combined with Allopurinol. Alprazolam The therapeutic efficacy of Alprazolam can be decreased when used in combination with Valomaciclovir. Amobarbital The serum concentration of Valomaciclovir can be decreased when it is combined with Amobarbital. Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Valomaciclovir. Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Valomaciclovir. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid esters
- Alternative Parents
- Valine and derivatives / 6-oxopurines / Hypoxanthines / Pyrimidones / Aminopyrimidines and derivatives / Fatty acid esters / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Carboxylic acid esters show 8 more
- Substituents
- 6-oxopurine / Alcohol / Alpha-amino acid ester / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Carbonyl group / Carboxylic acid ester show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- F094Y61748
- CAS number
- 195157-34-7
- InChI Key
- ATSZELKUSAREPW-ZJUUUORDSA-N
- InChI
- InChI=1S/C15H24N6O4/c1-8(2)10(16)14(24)25-4-3-9(6-22)5-21-7-18-11-12(21)19-15(17)20-13(11)23/h7-10,22H,3-6,16H2,1-2H3,(H3,17,19,20,23)/t9-,10+/m1/s1
- IUPAC Name
- (3R)-3-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methyl]-4-hydroxybutyl (2S)-2-amino-3-methylbutanoate
- SMILES
- CC(C)[C@H](N)C(=O)OCC[C@@H](CO)CN1C=NC2=C1N=C(N)NC2=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 168312
- ChEMBL
- CHEMBL2107301
- ZINC
- ZINC000005457090
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Herpes Zoster 1 1, 2 Completed Treatment Infectious Mononucleosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.03 mg/mL ALOGPS logP -0.78 ALOGPS logP -1.1 ChemAxon logS -2.1 ALOGPS pKa (Strongest Acidic) 10.17 ChemAxon pKa (Strongest Basic) 7.48 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 157.85 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 91.03 m3·mol-1 ChemAxon Polarizability 36.06 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on March 19, 2008 16:37 / Updated on February 21, 2021 18:52